These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25339037)

  • 1. Comprehensive analysis of temozolomide treatment for patients with glioma.
    Yang WB; Xing BZ; Liang H
    Asian Pac J Cancer Prev; 2014; 15(19):8405-8. PubMed ID: 25339037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.
    Dinnes J; Cave C; Huang S; Major K; Milne R
    Health Technol Assess; 2001; 5(13):1-73. PubMed ID: 11359682
    [No Abstract]   [Full Text] [Related]  

  • 3. Promises and controversies in the management of low-grade glioma.
    Stupp R; Baumert BG
    Ann Oncol; 2003 Dec; 14(12):1695-6. PubMed ID: 14630671
    [No Abstract]   [Full Text] [Related]  

  • 4. The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
    Wei W; Chen X; Ma X; Wang D; Guo Z
    J Neurooncol; 2015 Nov; 125(2):339-49. PubMed ID: 26334318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide dosing regimens for glioma patients.
    Strik HM; Marosi C; Kaina B; Neyns B
    Curr Neurol Neurosci Rep; 2012 Jun; 12(3):286-93. PubMed ID: 22437507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged administration of temozolomide in adult patients with anaplastic glioma.
    Freyschlag CF; Smolczyk DR; Janzen E; Schmieder K; Thomé C; Lohr F; Wenz F; Weiss C; Tuettenberg J; Seiz M
    Anticancer Res; 2011 Nov; 31(11):3873-7. PubMed ID: 22110212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
    Broniscer A; Chintagumpala M; Fouladi M; Krasin MJ; Kocak M; Bowers DC; Iacono LC; Merchant TE; Stewart CF; Houghton PJ; Kun LE; Ledet D; Gajjar A
    J Neurooncol; 2006 Feb; 76(3):313-9. PubMed ID: 16200343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
    Gupta T; Mohanty S; Moiyadi A; Jalali R
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1814-9. PubMed ID: 23764039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
    Bae SH; Park MJ; Lee MM; Kim TM; Lee SH; Cho SY; Kim YH; Kim YJ; Park CK; Kim CY
    J Korean Med Sci; 2014 Jul; 29(7):980-4. PubMed ID: 25045231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide for pediatric high-grade gliomas.
    Packer RJ
    Curr Neurol Neurosci Rep; 2012 Apr; 12(2):111-3. PubMed ID: 22249491
    [No Abstract]   [Full Text] [Related]  

  • 11. Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide.
    Sure D; Dunn I; Norden A; Anderson WS
    Clin Neurol Neurosurg; 2010 Oct; 112(8):741-2. PubMed ID: 20434832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide and treatment of malignant glioma.
    Friedman HS; Kerby T; Calvert H
    Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of temozolomide in children with recurrent high-grade glioma.
    Ruggiero A; Cefalo G; Garré ML; Massimino M; Colosimo C; Attinà G; Lazzareschi I; Maurizi P; Ridola V; Mazzarella G; Caldarelli M; Di Rocco C; Madon E; Abate ME; Clerico A; Sandri A; Riccardi R
    J Neurooncol; 2006 Mar; 77(1):89-94. PubMed ID: 16292488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Favourable result for temozolomide in recurrent high-grade glioma].
    Taal W; van der Rijt CD; Sillevis Smitt PA; Kros JM; van Heuvel I; Enting RH; van den Bent MJ
    Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1393-9. PubMed ID: 15997692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity.
    Lashkari HP; Saso S; Moreno L; Athanasiou T; Zacharoulis S
    J Neurooncol; 2011 Nov; 105(2):135-47. PubMed ID: 21748491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
    Broniscer A; Iacono L; Chintagumpala M; Fouladi M; Wallace D; Bowers DC; Stewart C; Krasin MJ; Gajjar A
    Cancer; 2005 Jan; 103(1):133-9. PubMed ID: 15565574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide: a milestone in neuro-oncology and beyond?
    Mutter N; Stupp R
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1187-204. PubMed ID: 16925485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide: a novel oral alkylating agent.
    Danson SJ; Middleton MR
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):13-9. PubMed ID: 12113120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.
    Motomura K; Natsume A; Wakabayashi T
    J Neurooncol; 2012 Jan; 106(1):209-11. PubMed ID: 21725854
    [No Abstract]   [Full Text] [Related]  

  • 20. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
    Levin VA
    Oncology (Williston Park); 2015 Apr; 29(4):264, 266-8. PubMed ID: 25952490
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.